• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Philip Morris International Inc

    5/14/26 10:19:20 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Philip Morris International Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    718172109

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    718172109


    1Names of Reporting Persons

    Capital Research Global Investors
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    79,806,976.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    79,856,361.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    79,856,361.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Philip Morris International Inc.
    (b)Address of issuer's principal executive offices:

    677 Washington Blvd, Ste. 1100, Stamford, CT 6901
    Item 2. 
    (a)Name of person filing:

    Capital Research Global Investors
    (b)Address or principal business office or, if none, residence:

    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c)Citizenship:

    N/A
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP Number(s):

    718172109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    79,856,361 ** **Capital Research Global Investors ("CRGI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CRGI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital Research Global Investors." CRGI is deemed to be the beneficial owner of 79,856,361 shares or 5.1% of the 1,558,530,268 shares believed to be outstanding.
    (b)Percent of class:

    5.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    79,806,976

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    79,856,361

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Capital Research Global Investors
     
    Signature:Jae Won Chung
    Name/Title:Vice President and Senior Counsel II, Capital Research and Management Company
    Date:05/11/2026
    Get the next $PM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    1/20/2026$180.00Buy → Hold
    Jefferies
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    More analyst ratings

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Counterfeit Cigarettes Drive EU Illicit Market Above 10% for First Time Since 2014

    Illicit cigarettes reached 10.3% of EU consumption in 2025 (41.8 billion), with an estimated €16.7 billion in lost tax revenues Counterfeits now lead the illicit market - accounting for 44% of EU illicit consumption (18.3 billion), up sharply year-on-year and displacing traditional East-to-West contraband flows Western Europe has the highest levels of illicit consumption, with France (41.4%), Belgium (24.8%), and the Netherlands (22.1%) among the most impacted. In France alone, counterfeit volumes reached nearly 10 billion cigarettes A new study detailing the scale of the illicit cigarette trade in the European Union (EU) shows that consumption of black-market cigarettes rose more

    6/3/26 4:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Participates in 2026 dbAccess Global Consumer Conference; Updates 2026 Full-Year Diluted EPS Forecast for Currency and Non-Cash Impairment Only

    Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, will address investors today at the 2026 dbAccess Global Consumer Conference in Paris at 11:15 a.m. CET (5:15 a.m. ET), including discussion of the following topics: PMI's continued expectation of a strong full-year performance, notably driven by the broad-based momentum of our international multicategory smoke-free business, led by IQOS. Recent heat-not-burn category developments broadly in-line with our expectations, most notably in Japan following the April 1, 2026 excise tax increase, with April offtake impacted by consumer pantry de-loading and IQOS maintaining a strong category sh

    6/2/26 1:30:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International to Host Webcast of Presentation at the 2026 dbAccess Global Consumer Conference

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live webcast of the company's remarks and Q&A session with Jacek Olczak, Group CEO PMI, at the 2026 dbAccess Global Consumer Conference on Tuesday, June 2, 2026, at approximately 11:15 a.m. CET (5:15 a.m. ET). The webcast will be available here, with a post-event recording available for one year at the same site. The webcast will provide a live stream of the entire PMI session and can also be accessed on mobile devices by downloading PMI's free Investor Relations Mobile App at www.pmi.com/irapp. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international

    5/26/26 7:29:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Combes Michel was granted 1,119 shares, increasing direct ownership by 11% to 11,643 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/8/26 2:01:23 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Geissler Werner was granted 1,119 shares, increasing direct ownership by 1% to 98,356 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/8/26 2:01:18 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Morparia Kalpana was granted 1,119 shares, increasing direct ownership by 4% to 28,236 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/8/26 2:01:11 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    SEC Filings

    View All

    Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    6/2/26 6:05:17 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SD filed by Philip Morris International Inc

    SD - Philip Morris International Inc. (0001413329) (Filer)

    5/22/26 6:02:19 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    5/20/26 7:05:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Philip Morris International downgraded by Jefferies with a new price target

    Jefferies downgraded Philip Morris International from Buy to Hold and set a new price target of $180.00

    1/20/26 9:10:49 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    PMI U.S. Expands Its Talent Pipeline and Welcomes New Class of Interns Across the Enterprise

    Intern class doubles to 25, signaling expanded investment in early-career talent STAMFORD, Conn., May 18, 2026 /PRNewswire/ -- Today, Philip Morris International's U.S. business (PMI U.S.) announced expanded internship and early‑career programs across the organization, underscoring its commitment to developing the next generation of talent to grow the business and innovate its industry. The programs are designed to provide meaningful experience, exposure, and opportunity for students just beginning their careers and early-career professionals ready to accelerate their impact. This summer, PMI U.S. will welcome its second intern

    5/18/26 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

    The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE:PM) today released a new white paper, "Human Cognition: The Next Frontier?", inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the "superskill" of the future, driving progress in an era of human-machine collaboration. As AI automates routine ta

    1/20/26 5:03:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Participates in 2026 dbAccess Global Consumer Conference; Updates 2026 Full-Year Diluted EPS Forecast for Currency and Non-Cash Impairment Only

    Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, will address investors today at the 2026 dbAccess Global Consumer Conference in Paris at 11:15 a.m. CET (5:15 a.m. ET), including discussion of the following topics: PMI's continued expectation of a strong full-year performance, notably driven by the broad-based momentum of our international multicategory smoke-free business, led by IQOS. Recent heat-not-burn category developments broadly in-line with our expectations, most notably in Japan following the April 1, 2026 excise tax increase, with April offtake impacted by consumer pantry de-loading and IQOS maintaining a strong category sh

    6/2/26 1:30:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2026 First-Quarter Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;

    Reported Diluted EPS declined by 9.3% to $1.56; Adjusted Diluted EPS grew by 16.0% to $1.96; and by 5.3% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2026 first quarter results.1 "Our performance exceeded our expectations in the first quarter, with an outstanding delivery from IQOS driving very good growth for the group against a strong prior-year comparison," said Jacek Olczak, Group CEO PMI. "Building on excellent broad-based momentum in the international smoke-free business and 16% adjusted diluted EPS growth in Q1, we are well positioned to continue delivering best-in-class performance in 2026." ____________________

    4/22/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Declares Regular Quarterly Dividend of $1.47 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.47 per common share, payable on April 13, 2026, to shareholders of record as of March 19, 2026. The ex-dividend date is March 19, 2026. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily

    3/5/26 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care